Biologic response modifiers: Indications, implications, and insights - 27/09/17
, Zuhair K. Ballas, MD bAbstract |
The field of biologic immune modulators is currently mushrooming at a dizzying pace. Although most of these biologics are tested and approved for one or a few indications, their unanticipated side effects and off-label use have contributed significantly to our understanding of basic immune mechanisms, the involvement of cytokines in several apparently nonimmunologic diseases, and the importance of compartmentalized immune responses. In this review we attempt to give a bird's-eye view of the major biologics and to highlight insights and implications derived from their secondary effects and adverse reactions.
Le texte complet de cet article est disponible en PDF.Key words : Biologics, biologic response modifiers, immune dysfunction, infection, autoimmunity, immunodeficiency
Abbreviations used : BRM, CNS, CTLA-4, IBD, PML, RA, Treg
Plan
| Disclosure of potential conflict of interest: Z. K. Ballas receives grant support from the Veteran's Administration; travel support from the American Academy of Allergy, Asthma & Immunology; and personal fees from the Immunodeficiency Foundation. B. P. Davis declares that he has no relevant conflicts of interest. |
Vol 139 - N° 5
P. 1445-1456 - mai 2017 Retour au numéro
Article précédent
- Omalizumab in children with uncontrolled allergic asthma: Review of clinical trial and real-world experience
- Bradley E. Chipps, Bob Lanier, Henry Milgrom, Antoine Deschildre, Gunilla Hedlin, Stanley J. Szefler, Meyer Kattan, Farid Kianifard, Benjamin Ortiz, Tmirah Haselkorn, Ahmar Iqbal, Karin Rosén, Benjamin Trzaskoma, William W. Busse
- The Editors' Choice
- Cezmi A. Akdis, Zuhair K. Ballas, Associate Editors of the JACI
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?